The reporter learned from the research team of the Joint Defense and Joint Control Mechanism of the State Council on the 14th that China's two new inactivated coronavirus vaccines have obtained the clinical trial license for the Phase I or II merger of the State Drug Administration, and related clinical trials have started simultaneously. This is the first batch of new inactivated coronavirus vaccine that has received clinical research approval.
These two new inactivated coronavirus vaccines were developed by Sinopharm Group China Bio-Wuhan Biological Products Research Institute and Beijing Kexing Zhongwei Biotechnology Co., Ltd. jointly with relevant scientific research institutions. Vaccines are essential for epidemic prevention and control. Since the outbreak, the research team of the Joint Defense and Joint Control Mechanism of the State Council has set up a special vaccine research and development team, and laid out a total of 5 technical routes based on inactivated vaccines, recombinant protein vaccines, adenovirus vector vaccines, attenuated influenza virus vector live vaccines, and nucleic acid vaccines.12 This research and development task is currently steadily advancing. Prior to this, the adenovirus vector vaccine of the Academy of Military Medical Sciences of the Academy of Military Sciences has been approved for clinical trials. The inactivated vaccine approved for clinical trials this time is a vaccine that kills pathogenic microorganisms but still maintains its immunogenicity. It has the advantages of mature production technology, controllable quality standards, and wide protection. , And there are internationally accepted standards to judge the safety and effectiveness of vaccines. The inactivated vaccines in China have a good research foundation. Inactivated hepatitis A vaccine, inactivated influenza (split) vaccine, inactivated hand, foot and mouth disease vaccine, and inactivated polio vaccine have been widely used. It is understood that the above-mentioned enterprises that have obtained clinical trial licenses have the capacity to produce large-scale inactivated vaccines. According to relevant national laws and regulations, they are ready for emergency use.